334 related articles for article (PubMed ID: 33921915)
1. Current Status of Gene Therapy Research in Polyglutamine Spinocerebellar Ataxias.
Afonso-Reis R; Afonso IT; Nóbrega C
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921915
[TBL] [Abstract][Full Text] [Related]
2. Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias.
Buijsen RAM; Toonen LJA; Gardiner SL; van Roon-Mom WMC
Neurotherapeutics; 2019 Apr; 16(2):263-286. PubMed ID: 30607747
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics and Possible Drug Targets in Autosomal Dominant Spinocerebellar Ataxias.
Szpisjak L; Zadori D; Klivenyi P; Vecsei L
CNS Neurol Disord Drug Targets; 2019; 18(4):279-293. PubMed ID: 30864514
[TBL] [Abstract][Full Text] [Related]
4. Gene Therapy for Polyglutamine Spinocerebellar Ataxias: Advances, Challenges, and Perspectives.
Vázquez-Mojena Y; León-Arcia K; González-Zaldivar Y; Rodríguez-Labrada R; Velázquez-Pérez L
Mov Disord; 2021 Dec; 36(12):2731-2744. PubMed ID: 34628681
[TBL] [Abstract][Full Text] [Related]
5. Molecular Mechanisms and Therapeutic Strategies in Spinocerebellar Ataxia Type 7.
Karam A; Trottier Y
Adv Exp Med Biol; 2018; 1049():197-218. PubMed ID: 29427104
[TBL] [Abstract][Full Text] [Related]
6. Spinocerebellar ataxias caused by polyglutamine expansions: a review of therapeutic strategies.
Underwood BR; Rubinsztein DC
Cerebellum; 2008; 7(2):215-21. PubMed ID: 18418676
[TBL] [Abstract][Full Text] [Related]
7. Autosomal-dominant cerebellar ataxias.
Mundwiler A; Shakkottai VG
Handb Clin Neurol; 2018; 147():173-185. PubMed ID: 29325610
[TBL] [Abstract][Full Text] [Related]
8. Gene Deregulation and Underlying Mechanisms in Spinocerebellar Ataxias With Polyglutamine Expansion.
Niewiadomska-Cimicka A; Hache A; Trottier Y
Front Neurosci; 2020; 14():571. PubMed ID: 32581696
[TBL] [Abstract][Full Text] [Related]
9. Spinocerebellar ataxias: prospects and challenges for therapy development.
Ashizawa T; Öz G; Paulson HL
Nat Rev Neurol; 2018 Oct; 14(10):590-605. PubMed ID: 30131520
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.
Fiszer A; Olejniczak M; Switonski PM; Wroblewska JP; Wisniewska-Kruk J; Mykowska A; Krzyzosiak WJ
BMC Mol Biol; 2012 Mar; 13():6. PubMed ID: 22397573
[TBL] [Abstract][Full Text] [Related]
11. Splice isoform-specific suppression of the Cav2.1 variant underlying spinocerebellar ataxia type 6.
Tsou WL; Soong BW; Paulson HL; Rodríguez-Lebrón E
Neurobiol Dis; 2011 Sep; 43(3):533-42. PubMed ID: 21550405
[TBL] [Abstract][Full Text] [Related]
12. Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development.
Chen ML; Lin CC; Rosenthal LS; Opal P; Kuo SH
J Neurol Sci; 2021 May; 424():117417. PubMed ID: 33836316
[TBL] [Abstract][Full Text] [Related]
13. Visual oculomotor abnormalities and vestibulo‑ocular reflex dynamics in polyglutamine spinocerebellar ataxias (Review).
Peng Y; Tu Q; Han Y; Wan C; Gao L
Exp Ther Med; 2023 Jul; 26(1):358. PubMed ID: 37324515
[TBL] [Abstract][Full Text] [Related]
14. Polyglutamine spinocerebellar ataxias: emerging therapeutic targets.
Neves-Carvalho A; Duarte-Silva S; Teixeira-Castro A; Maciel P
Expert Opin Ther Targets; 2020 Nov; 24(11):1099-1119. PubMed ID: 32962458
[TBL] [Abstract][Full Text] [Related]
15. [Advance in research on spinocerebellar ataxia 2].
Jing F; Yang D; Chen T
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2018 Apr; 35(2):284-287. PubMed ID: 29653012
[TBL] [Abstract][Full Text] [Related]
16. Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia.
Torashima T; Koyama C; Iizuka A; Mitsumura K; Takayama K; Yanagi S; Oue M; Yamaguchi H; Hirai H
EMBO Rep; 2008 Apr; 9(4):393-9. PubMed ID: 18344973
[TBL] [Abstract][Full Text] [Related]
17. Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies.
McIntosh CS; Li D; Wilton SD; Aung-Htut MT
Biomedicines; 2021 Oct; 9(11):. PubMed ID: 34829728
[TBL] [Abstract][Full Text] [Related]
18. Polyglutamine (PolyQ) diseases: genetics to treatments.
Fan HC; Ho LI; Chi CS; Chen SJ; Peng GS; Chan TM; Lin SZ; Harn HJ
Cell Transplant; 2014; 23(4-5):441-58. PubMed ID: 24816443
[TBL] [Abstract][Full Text] [Related]
19. Mini-review: spinocerebellar ataxias: an update of SCA genes.
Trott A; Houenou LJ
Recent Pat DNA Gene Seq; 2012 Aug; 6(2):115-21. PubMed ID: 22670601
[TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanisms and Therapeutics for Spinocerebellar Ataxia Type 2.
Egorova PA; Bezprozvanny IB
Neurotherapeutics; 2019 Oct; 16(4):1050-1073. PubMed ID: 31435879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
